Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

《Translational Psychiatry》是一本由SPRINGERNATURE出版商出版的专业医学期刊，该刊创刊于2011年，刊期1 issue/year，该刊已被国际权威数据库SCIE收录。在中科院最新升级版分区表中，该刊分区信息为大类学科：医学 2区，小类学科：精神病学 2区；在JCR（Journal Citation Reports）分区等级为Q1。该刊发文范围涵盖精神病学等领域，旨在及时、准确、全面地报道国内外精神病学工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等，促进学术交流，鼓励学术创新。2021年影响因子为7.989，平均审稿速度23 Weeks。